Third consensus on medical treatment of metastatic breast cancer.

BACKGROUND Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care measures. DESIGN To provide timely and evidence-based recommendations for the diagnostic workup and treatment of patients with MBC, an international expert panel reviewed and discussed the evidence available from clinical trials regarding diagnostic, therapeutic and supportive measures with emphasis on their impact on the quality of life and overall survival of patients with MBC. RESULTS Evidence-based recommendations for the diagnostic workup, endocrine therapy, chemotherapy, use of targeted therapies and bisphosphonates, surgical treatment and supportive care measures in the management of patients with MBC were formulated. CONCLUSIONS The present consensus manuscript updates evidence-based recommendations for state-of-the-art treatment of MBC depending on disease-associated and biological variables.

[1]  C. Vogel,et al.  High dose estrogen as a salvage hormonal strategy for highly refractory metastatic breast cancer (MBC): “back to the future.”. , 2009 .

[2]  H. Gómez,et al.  Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial. , 2009 .

[3]  D. Jeffe,et al.  A randomized phase 2 trial of low dose (6 mg daily) versus high dose (30 mg daily) estradiol for patients with estrogen receptor positive aromatase inhibitor resistant advanced breast cancer. , 2009 .

[4]  W. Alexander,et al.  American Society of Clinical Oncology , 2020, Definitions.

[5]  Barbara L. Smith,et al.  Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival , 2009, Breast Cancer Research and Treatment.

[6]  H. Gómez,et al.  Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Avis.  Breast cancer survivors and hot flashes: the search for nonhormonal treatments. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Keith,et al.  Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Esteva,et al.  Serum HER‐2/neu and relative resistance to trastuzumab‐based therapy in patients with metastatic breast cancer , 2008, Cancer.

[10]  Allen S Melemed,et al.  Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Gómez,et al.  Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Moulder.  Ixabepilone for the treatment of taxane-refractory breast cancer. , 2008, Future oncology.

[13]  S. Franco,et al.  A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Carmichael,et al.  AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study , 2008 .

[15]  J. Baselga,et al.  A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy , 2008 .

[16]  K. Gelmon,et al.  Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy , 2008 .

[17]  O. Nanni,et al.  A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC) , 2008 .

[18]  N. Harbeck,et al.  Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. , 2008 .

[19]  J. Niland,et al.  Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN) , 2008 .

[20]  M. Inbar,et al.  Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine , 2008 .

[21]  S. Loibl,et al.  Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3–05) , 2008 .

[22]  C. Perou,et al.  TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer , 2008 .

[23]  S. Hilsenbeck,et al.  Association of Surgery With Improved Survival in Stage IV Breast Cancer Patients , 2008, Annals of surgery.

[24]  Melissa Bondy,et al.  Residual risk of breast cancer recurrence 5 years after adjuvant therapy. , 2008, Journal of the National Cancer Institute.

[25]  Tomasz Burzykowski,et al.  Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. D. Van den Abbeele,et al.  Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  H. Rugo,et al.  Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Baogang J. Xu,et al.  Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. , 2008, Journal of proteome research.

[29]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Hortobagyi,et al.  Timing of Surgical Intervention for the Intact Primary in Stage IV Breast Cancer Patients , 2008, Annals of Surgical Oncology.

[31]  B. Overmoyer.  Options for the treatment of patients with taxane-refractory metastatic breast cancer. , 2008, Clinical breast cancer.

[32]  D. Dorr,et al.  Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. , 2008, JAMA.

[33]  I. Smith,et al.  Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Mariaelena Pierobon,et al.  Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. , 2008, Journal of proteome research.

[35]  M. Gnant,et al.  Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer , 2008, Cancer Chemotherapy and Pharmacology.

[36]  M. Aapro,et al.  The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. , 2008, European journal of cancer.

[37]  H. Mouridsen,et al.  Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group , 2008, Acta oncologica.

[38]  M. Somerfield,et al.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Somerfield,et al.  Guideline summary: use of epoetin and darbepoetin in patients with cancer-2007 american society of clinical oncology/american society of hematology clinical practice guideline update. , 2008, Journal of oncology practice.

[40]  E. Stadtmauer.  A dramatic story of hope and reality. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Hortobagyi,et al.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  M. Somerfield,et al.  Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. , 2008, Blood.

[43]  B. Thürlimann,et al.  Capecitabine and Vinorelbine as First-Line Treatment in Elderly Patients (≥65 Years) with Metastatic Breast Cancer , 2008, Oncology.

[44]  M. Casey,et al.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses , 2008, Breast Cancer Research and Treatment.

[45]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[46]  W. M. Smit,et al.  A phase III study on the efficacy and safety of docetaxel, every three weeks or as a weekly regimen in patients with metastatic breast cancer , 2007 .

[47]  C. Hudis,et al.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  H. Gómez,et al.  Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Castiglione‐Gertsch,et al.  Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. , 2007, The Lancet. Oncology.

[50]  D. Leach,et al.  Perspectives on the development of a therapeutic HER-2 cancer vaccine. , 2007, Vaccine.

[51]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[52]  Michael Gnant,et al.  Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  D. Jeffe,et al.  Surgical Resection of the Primary Tumor is Associated with Increased Long-Term Survival in Patients with Stage IV Breast Cancer after Controlling for Site of Metastasis , 2007, Annals of Surgical Oncology.

[54]  C. Vogel,et al.  Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. , 2007, Clinical breast cancer.

[55]  E. Yang,et al.  Advances of MUC1 as a target for breast cancer immunotherapy. , 2007, Histology and histopathology.

[56]  R. Tuma.  Inconsistency of HER2 test raises questions. , 2007, Journal of the National Cancer Institute.

[57]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  J. Forbes,et al.  BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) , 2007 .

[59]  M. Margelí,et al.  Prolongation of TTP by maintenance therapy with PLD in a multicenter phase III randomized trial following standard chemotherapy for MBC: GEICAM 2001-01 study , 2007 .

[60]  W. Gradishar,et al.  Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC) , 2007 .

[61]  A. Tolcher,et al.  A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC) , 2007 .

[62]  M. Stockler,et al.  A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC) , 2007 .

[63]  V. Beral.  Ovarian cancer and hormone replacement therapy in the Million Women Study , 2007, The Lancet.

[64]  E. Eriksen,et al.  Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. , 2007, Critical reviews in oncology/hematology.

[65]  Wolfgang Heller,et al.  Triple-negative breast cancer: therapeutic options. , 2007, The Lancet. Oncology.

[66]  A. Ruíz,et al.  Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. , 2007, The Lancet. Oncology.

[67]  G. Sledge,et al.  Drug Insight: VEGF as a therapeutic target for breast cancer , 2007, Nature Clinical Practice Oncology.

[68]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[69]  M. Stockler,et al.  Second consensus on medical treatment of metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  J. O’Shaughnessy,et al.  Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer , 2007 .

[71]  J. Jassem,et al.  Evaluation of trastuzumab (Herceptin®), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer , 2007 .

[72]  M. Piccart,et al.  A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. , 2007, Critical reviews in oncology/hematology.

[73]  Christophe Tournigand,et al.  Impact of chemotherapy beyond the first line in patients with metastatic breast cancer , 2007, Breast Cancer Research and Treatment.

[74]  G. Steger,et al.  Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer , 2007, Breast Cancer Research and Treatment.

[75]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[76]  D. Bruno,et al.  Management of postmenopausal symptoms in breast cancer survivors. , 2006, Seminars in oncology.

[77]  C. Hudis,et al.  Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[78]  Thomas J. Smith,et al.  American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.

[80]  N. Kearney,et al.  EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. , 2006, European journal of cancer.

[81]  O. Nanni,et al.  Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  S. Dalal,et al.  Pathophysiology and management of hot flashes. , 2006, The journal of supportive oncology.

[83]  G. Pond,et al.  Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  G. Cervantes,et al.  Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  L. Bosserman,et al.  Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Ahmedin Jemal,et al.  Trends in Breast Cancer by Race and Ethnicity: Update 2006 , 2006, CA: a cancer journal for clinicians.

[88]  G. Hortobagyi,et al.  Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor , 2006, Annals of Surgical Oncology.

[89]  W. Ershler.  Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. , 2006, The oncologist.

[90]  M. Dowsett,et al.  Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  A. Goldhirsch,et al.  Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[92]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[93]  S. Ruggiero,et al.  Bisphosphonate complications including osteonecrosis of the jaw. , 2006, Hematology. American Society of Hematology. Education Program.

[94]  A. Mariotti,et al.  Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. , 2006, Journal of the American Dental Association.

[95]  G. Steger,et al.  Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study , 2006, BMC Cancer.

[96]  N. Gabrail,et al.  Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. , 2005, Clinical breast cancer.

[97]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[99]  B. Sarg,et al.  Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. , 2005, European journal of cancer.

[100]  M. Hickey,et al.  Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. , 2005, The Lancet. Oncology.

[101]  J. Baselga,et al.  Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Suzanne F. Jones,et al.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  C. Vogel,et al.  Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.

[105]  R. Simes,et al.  A systematic review of taxane-containing regimens for metastatic breast cancer , 2005, British Journal of Cancer.

[106]  C. Osborne,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma , 2005, Cancer.

[107]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  O. Nanni,et al.  Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study , 2005 .

[109]  H. Gómez,et al.  A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer , 2005 .

[110]  A. Schneeweiss,et al.  Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study , 2005 .

[111]  D. Tripathy,et al.  First-Line Treatment with Bevacizumab and Paclitaxel Prolongs Progression-Free Survival in Metastatic Breast Cancer , 2005 .

[112]  C. Szczylik,et al.  Central nervous system metastases in breast cancer patients administered trastuzumab. , 2005, Cancer treatment reviews.

[113]  D. Doval,et al.  First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[114]  Y. Ohashi,et al.  Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[116]  M. Ellis,et al.  Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  J. Baselga,et al.  Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  L. Mariani,et al.  Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  M. Inbar,et al.  Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[121]  A. Howell,et al.  P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases , 2005 .

[122]  P Kelly Marcom,et al.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  N. Sneige,et al.  Estrogen Receptor Analysis for Breast Cancer: Current Issues and Keys to Increasing Testing Accuracy , 2005, Advances in anatomic pathology.

[124]  D. Ghersi,et al.  Single agent versus combination chemotherapy for metastatic breast cancer. , 2005, The Cochrane database of systematic reviews.

[125]  F. Cappuzzo,et al.  Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer , 2005, Breast Cancer Research and Treatment.

[126]  L. Rosen,et al.  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion , 2004, Cancer.

[127]  L. Schwartzberg,et al.  A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. , 2004, The oncologist.

[128]  V. Georgoulias,et al.  Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  R. Bell,et al.  Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer , 2004, Pain.

[130]  S. Culine,et al.  Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer , 2004, British Journal of Cancer.

[131]  P. Conte,et al.  Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. , 2004, The oncologist.

[132]  J B Vermorken,et al.  A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[133]  N. Weidner,et al.  Her2 Amplification: Correlation of Chromogenic In Situ Hybridization With Immunohistochemistry and Fluorescence In Situ Hybridization , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[134]  N. Dandachi,et al.  Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancer , 2004, Journal of Molecular Histology.

[135]  S. Nag,et al.  Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  J. Isola,et al.  Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization , 2004, Clinical Cancer Research.

[137]  J. Peterse,et al.  Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study , 2004, Virchows Archiv.

[138]  H. Burris,et al.  Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.

[139]  J. O’Shaughnessy,et al.  Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. , 2004, Clinical breast cancer.

[140]  D. Berry,et al.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[141]  M. Gnant,et al.  Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study , 2004, Journal of Cancer Research and Clinical Oncology.

[142]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  Suzanne F. Jones,et al.  Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  S. Martino,et al.  A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer , 2004, Breast Cancer Research and Treatment.

[145]  M. Cobleigh,et al.  Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[147]  M. Stockler,et al.  Consensus on Medical Treatment of Metastatic Breast Cancer , 2003, Breast Cancer Research and Treatment.

[148]  E. Stadtmauer.  High Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Breast Cancer: Is there a Place? , 2003, Breast Cancer Research and Treatment.

[149]  C. Zielinski,et al.  Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer , 2003, Breast Cancer Research and Treatment.

[150]  M. Stockler,et al.  Chemotherapy for Advanced Breast Cancer – How Long Should it Continue? , 2003, Breast Cancer Research and Treatment.

[151]  J. Jassem.  Chemotherapy of Metastatic Breast Cancer: Is more better? , 2003, Breast Cancer Research and Treatment.

[152]  J. Nortier,et al.  Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer , 2000, Breast Cancer Research and Treatment.

[153]  H. Friess,et al.  Oligoclonal T-cell populations in an inflammatory pseudotumor of the pancreas possibly related to autoimmune pancreatitis: an immunohistochemical and molecular analysis , 2004, Virchows Archiv.

[154]  J. Cauley,et al.  American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  K. Gelmon,et al.  Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  J. Robertson,et al.  Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. , 2003, European journal of cancer.

[157]  R. Thomas,et al.  An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. , 2003, European journal of cancer.

[158]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[159]  M. Lichinitser,et al.  Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[160]  M. Piccart,et al.  Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[161]  J. Isola,et al.  Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? , 2003, Clinical breast cancer.

[162]  E. Winer,et al.  Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  J. Robertson,et al.  Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. , 2003, European journal of cancer.

[164]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  D. Ghersi,et al.  Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. , 2003, The Cochrane database of systematic reviews.

[166]  M. Krzakowski,et al.  Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  J. Klijn,et al.  Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. , 2003, European journal of cancer.

[168]  D. Neuberg,et al.  Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  P. Pedrazzoli,et al.  Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin- Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma , 2003, Journal of chemotherapy.

[170]  G. Sledge.  Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. , 2001, Oncology.

[171]  S. Singletary,et al.  Revision of breast cancer staging: the 6th edition of the TNM Classification. , 2003, Seminars in surgical oncology.

[172]  M. Toi,et al.  Weekly schedule of docetaxel in breast cancer: Evaluation of response and toxicity , 2003, Breast cancer.

[173]  Christina J. Herold,et al.  Consensus on medical treatment of non-small cell lung cancer. , 2002, Lung cancer.

[174]  J. Mortimer,et al.  Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. , 2002, The oncologist.

[175]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[176]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  M. Piccart,et al.  Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[178]  David Miles,et al.  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[181]  F. Hirsch,et al.  Consensus on medical treatment of non-small cell lung cancer , 2002 .

[182]  Lyndsay Harris,et al.  Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma , 2002, Cancer.

[183]  E. Perez,et al.  Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[184]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[185]  E. Rubenstein,et al.  NCCN: Fever and neutropenia. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[186]  L. Zelek,et al.  Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma , 2001, Cancer.

[187]  H. Burger,et al.  Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[188]  M. Morgan,et al.  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[189]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[190]  R. Rosso,et al.  Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[192]  J. Jassem,et al.  Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[193]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  R. Blamey,et al.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  G. Mills,et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  L. Mauriac,et al.  [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases]. , 2001, Bulletin du cancer.

[197]  Larry L. Constantine,et al.  Back to the future , 2001, CACM.

[198]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[199]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[200]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[201]  P. Lønning,et al.  Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  J. Klijn,et al.  Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. , 2000, Journal of the National Cancer Institute.

[203]  C. Tinelli,et al.  Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer. , 2000, International journal of oncology.

[204]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[205]  M. Somerfield,et al.  Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines. Health Services Research Committee of the American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[207]  D. Slamon,et al.  Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. , 1999, Seminars in oncology.

[208]  M. Groenvold,et al.  Oral clodronate in breast cancer patients with bone metastases: a randomized study , 1999, Journal of internal medicine.

[209]  G. Hortobagyi,et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[210]  I. Tannock,et al.  Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  Anthony Howell,et al.  Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma , 1998, Cancer.

[213]  G. Hortobagyi,et al.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  G. Sledge,et al.  Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[215]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  R. Paridaens,et al.  Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. , 1997, European journal of cancer.

[217]  A Howell,et al.  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[218]  A. Buzdar,et al.  Fadrozole HCL (CGS‐16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials , 1996, Cancer.

[219]  K. Gelmon,et al.  Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[220]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[221]  T. Powles,et al.  Breast cancer response to hormone replacement therapy withdrawal , 1995, The Lancet.

[222]  M. Dhodapkar,et al.  Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. , 1995, Cancer.

[223]  A. Howell,et al.  A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. , 1995, European journal of cancer.

[224]  P. Sismondi,et al.  Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[225]  R Bicknell,et al.  Angiogenesis in Breast Cancer , 1993 .

[226]  C. Focan,et al.  Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[227]  C. Blomqvist,et al.  Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[228]  T. Powles,et al.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[229]  C. Spurr,et al.  Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.